Intellipharmaceutics International Inc. (IPCI)

[numbersarefun]

Collegium reported revenue of $408K for 3rd quarter. So Collegium captured about 0.008% market share, assuming Oxycontin does $550 million a quarter. Collegium's Xtampza is having a hard time competing against Oxycontin. I think Rexista will have a hard time competing against Oxycontin also. There is little incentive for existing Oxycontin users to switch. You also have to convince doctors to prescribe your new drug over Oxycontin.

Xtampza had a full quarter of sales. It was launched mid-June and 3rd quarter ended in September. Revenue was $408K and cost of product revenue was $29K, which is a gross profit margin of 92%. Selling and general expenses increased $17.7 million from last year.

Collegium has a large market capitalization because it raised a lot of capital from the public markets. Collegium spent a lot to cash to launch Xtampza, and has $91 million of cash left. Collegium went IPO in 2015 at around $12 a share.


Collegium Reports Third Quarter Financial Results, Nov. 10, 2016:
http://ir.collegiumpharma.com/phoenix.zhtml?c=253995&p=irol-newsArticle&ID=2221547